Cargando…
High prevalence of ECG variations and abnormalities in young and healthy TaMoVac 01 HIV vaccine trial volunteers from Tanzania
Autores principales: | Mann, PJ, Munseri, P, Kaluwa, B, Missanga, M, Lwakatare, J, Hoelscher, M, Bakari, M, Janabi, M, Maboko, L, Sandström, E, Kroidl, A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441374/ http://dx.doi.org/10.1186/1742-4690-9-S2-P114 |
Ejemplares similares
-
Enrolment and logistical challenges in TaMoVac 01 Phase I/II HIV trial despite the completion of an earlier (HIVIS-03 trial trial) in Dar es Salaam
por: Ngatoluwa, M, et al.
Publicado: (2012) -
Experience in recruiting youths in HIV vaccine trials in Tanzania: the TaMoVac 01 study
por: Massawa, T, et al.
Publicado: (2012) -
Preferential targeting of conserved Gag regions after vaccination with a heterologous DNA prime Modified Vaccinia Ankara boost HIV vaccine regime
por: Bauer, A, et al.
Publicado: (2012) -
Breadth, phenotype and functionality of Gag-specific T cell responses induced by a heterologous DNA/MVA prime-boost HIV-1 vaccine regimen
por: Podola, L, et al.
Publicado: (2012) -
Priming with a Simplified Intradermal HIV-1 DNA Vaccine Regimen followed by Boosting with Recombinant HIV-1 MVA Vaccine Is Safe and Immunogenic: A Phase IIa Randomized Clinical Trial
por: Munseri, Patricia. J., et al.
Publicado: (2015)